Fluge and Mella's search for genetic markers

In Dr. Albright’s study of the families of ME/CFS patients in Utah, risk of ME was found to be 2.7 times greater in first-degree relatives of ME patients, 2.3 times greater in second-degree relatives, and 1.93 times greater in third-degree relatives.  This familial clustering is the basis for new research in Norway, where scientists are doing their best to discover what genes cause or contribute to the development of myalgic encephalomyelitis.  One of the areas of interest is the HLA gene, which has been linked to many autoimmune conditions, including lupus, Sjögren’s Syndrome, and autoimmune hepatitis.  Researchers at Oslo University Hospital are currently examining the HLA gene in ME.
Research is also underway at Haukeland University, where Fluge, Mella, and Bruland are finding genetic mutations that family members with ME have in common.  By looking at the genes of healthy and unhealthy members of the same families, they will be able to start identifying genetic risk factors for the illness.
Researchers are using exome sequencing in order to determine where mutations occur in the genes of people with ME.  The exome is the part of DNA that codes for all the proteins in the patient’s body.  Though the exome makes up only 1.5% of the DNA in the cell, approximately 85% of disease-causing mutations are located there.  The researchers are also examining the flanking intron — the DNA that precedes and follows the exon — in case mutations occur there.
Fluge et al. have completed exome sequencing for 18 people from two different families, and have begun complete exome sequencing in a third.  However, they have already discovered a genetic mutation that may have the potential to be the culprit: a mutation that occurs in 1 of every 500 people in the European general population.  This same variant has been observed in several of the subjects in their Rituximab study.
In order to study this variant in more detail, the researchers performed skin biopsies on ME patients — since all the patients’ cells will have this same mutation — and used these to cultivate samples of cells with the mutation.
Finally, Fluge et al. created cells in which this mutation was inserted, using a process called gene transfection, and dramatically increased the effect of the mutation on the cell.  The researchers hope that by increasing the gene’s activity, they can better observe the effect the mutation has on cellular processes.
Fluge et al. believe that the genetic mutations they uncover will have a direct effect on which symptoms predominate in each family.  They are also hopeful that, by finding the right mutation, they can better understand the mechanism of the disease.  Hopefully, these early findings will be repeated in other families Fluge and Mella study, as their research continues.

Facebook
Twitter
WhatsApp
Email

Latest News

reddish rectangle image with different color stripes of red coming out at a diagonal from the center. In the center is the TeachMETreatME logo. The words celebrating an impactful campaign in white font underneath the logo.

#TeachMETreatME: Celebrating An Impactful Campaign

We are THRILLED to share the rolling successes of our #TeachMETreatME campaign with you, as we report back on the amazing medical education events that have taken place so far – with many more to come in the upcoming months! (And don’t miss the global #MillionsMissing events later in the article!) Over the past several

Read More »

#MillionsMissing Week is Here: #TeachMETreatME in Action!

We are excited to announce the kick-off of #MillionsMissing 2024 – our ongoing campaign to Teach ME and Treat ME by educating medical providers across our nation’s hospital systems and medical schools about myalgic encephalomyelitis (ME).  Throughout the spring, summer and fall, #MEAction teams are hosting 13 medical education events to encourage medical providers to

Read More »

#MEAction’s Jaime Seltzer Selected for TIME100 Health 2024

We are thrilled to share with you that Jaime Seltzer, #MEAction’s Scientific Director, has been selected for TIME100 Health 2024, TIME’s new annual list of 100 individuals who most influenced global health this year! This is a huge honor based on years of work fighting for equity for people with ME.  We intimately know the

Read More »
Scroll to Top